Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide

BJU International

Volumn 89, Issue 6, 2002, Pages 591-595

  Douglas, M L ^a   Reid, J L ^a   Hii, S I ^a   Jonsson, J R ^a   Nicol, D L ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Antitumour assays; Fibroblast growth factor; Integrins; Tumour necrosis factor; Xenograft model

Indexed keywords

BETA3 INTEGRIN; FIBROBLAST GROWTH FACTOR 2; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; RNA EXTRACTION; SCID MOUSE; TRANSCRIPTION REGULATION; TREATMENT FAILURE; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THALIDOMIDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036347153     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02666.x     Document Type: Article

References (19)

1. Vascular endothelial growth factor expression is increased in renal cell carcinoma
2. Biological role of HGF/MET pathway in renal cell carcinoma
3. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma
4. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
5. Mechanism of action in thalidomide teratogenesis
6. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
7. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid
8. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1
9. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains. Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis
10. Continuous low dose Thalidomide. A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
11. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction
12. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
13. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice
14. The effect of thalidomide on experimental tumors and metastases
15. Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma
16. Myoblast alpha v beta3 integrin levels are controlled by transcriptional regulation of expression of the beta3 subunit and down-regulation of beta3 subunit expression is required for skeletal muscle cell differentiation
17. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
18. Phase II evaluation of thalidomide in patients with metastatic breast cancer
19. Genetic heterogeneity of angiogenesis in mice